A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-Maintenance
William J. Sandborn(University of San Diego), Paul Rutgeerts(KU Leuven), Gunnar Järnerot(Örebro University Hospital), Colleen Marano(Johnson & Johnson (United States)), Richard Strauss, J. Collins, Cynthia Guzzo(Janssen (Belgium)), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Walter Reinisch(Medical University of Vienna), Jewel Johanns(Johnson & Johnson (United States)), Brian Feagan, Hongyan Zhang(Northwest A&F University), Peter G. Gibson(University Gastroenterology)
Cited by 1
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k